Uncategorized
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline.
The drug litifilimab improved patients’ skin lesions after 24 weeks, with 14.7% reaching … Read More